BLOOD COAGULATION & FIBRINOLYSIS

Scope & Guideline

Illuminating the Pathways of Coagulation and Fibrinolysis

Introduction

Explore the comprehensive scope of BLOOD COAGULATION & FIBRINOLYSIS through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore BLOOD COAGULATION & FIBRINOLYSIS in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0957-5235
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1990 to 2024
AbbreviationBLOOD COAGUL FIBRIN / Blood Coagul. Fibrinolysis
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The journal 'Blood Coagulation & Fibrinolysis' focuses on a wide range of topics related to hemostasis, thrombosis, and bleeding disorders. It aims to disseminate cutting-edge research findings that contribute to the understanding and management of coagulation disorders, with a strong emphasis on clinical implications and biochemical mechanisms.
  1. Coagulation Disorders and Thrombosis:
    The journal covers various aspects of coagulation disorders, including inherited and acquired thrombophilias, immune thrombocytopenic purpura, and other thrombotic conditions, focusing on their pathophysiology, diagnosis, and management.
  2. Clinical Outcomes and Treatment Strategies:
    Research published in the journal often explores clinical outcomes associated with different treatment modalities, including novel therapies for hemophilia, anticoagulation strategies, and the effectiveness of new drugs.
  3. Laboratory Diagnostics and Methodologies:
    A significant part of the journal is dedicated to advancements in laboratory diagnostics, including the evaluation of coagulation assays, thromboelastometry, and the development of new diagnostic techniques for bleeding disorders.
  4. Genetic and Molecular Studies:
    The journal also emphasizes genetic studies related to coagulation factors and their mutations, providing insights into the molecular basis of bleeding disorders and potential therapeutic targets.
  5. Epidemiological Studies:
    Epidemiological research focusing on the prevalence, risk factors, and socio-economic impact of coagulation disorders is a key area of interest, contributing to the understanding of these conditions at a population level.
The journal has shown an evolving focus on several emerging themes that reflect current trends in hematology and coagulation research. These themes indicate the journal's responsiveness to new challenges and advancements in the field.
  1. Impact of COVID-19 on Coagulation:
    Research investigating the effects of COVID-19 on coagulation and thrombotic risk has surged, reflecting the pandemic's significant impact on health and its implications for patients with pre-existing coagulation disorders.
  2. Innovative Therapies and Treatments:
    There is an increasing number of studies focusing on innovative therapies for treating thrombotic and bleeding disorders, including targeted therapies and novel agents like caplacizumab and emicizumab.
  3. Real-World Evidence and Outcomes Research:
    The journal is increasingly publishing studies that provide real-world evidence regarding treatment outcomes, emphasizing the importance of clinical effectiveness data in everyday practice.
  4. Integration of Genetic Testing in Management:
    Emerging themes include the integration of genetic testing into the management of coagulation disorders, highlighting the growing importance of personalized medicine in this field.
  5. Interdisciplinary Approaches to Hemostasis:
    There is a trend towards interdisciplinary research that incorporates insights from immunology, oncology, and infectious diseases, reflecting the complex interactions between coagulation and other bodily systems.

Declining or Waning

While the journal maintains a broad focus, certain themes appear to be declining in prominence based on recent publications. This may reflect shifts in research priorities or advancements in understanding that reduce the need for certain types of studies.
  1. Traditional Anticoagulation Therapies:
    There has been a noticeable decrease in studies solely focused on traditional anticoagulation therapies such as warfarin, as newer direct oral anticoagulants gain prominence and become the focus of research.
  2. Case Reports of Rare Disorders:
    The frequency of case reports detailing rare coagulation disorders seems to be waning, possibly due to a shift towards more comprehensive studies that aggregate data across multiple cases rather than focusing on singular instances.
  3. Basic Science Studies:
    Basic science studies that explore fundamental mechanisms of coagulation without direct clinical applications are appearing less frequently, as the journal pivots towards research with immediate clinical relevance.
  4. Historical Perspectives on Coagulation Disorders:
    There is a decline in publications that address historical perspectives or traditional views on coagulation disorders, indicating a shift towards contemporary and evidence-based practices.

Similar Journals

BLOOD REVIEWS

Advancing the frontiers of Hematology and Oncology.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

Leukemia Research Reports

Fostering collaboration for a leukemia-free future.
Publisher: ELSEVIER ADVANCED TECHNOLOGYISSN: 2213-0489Frequency: 2 issues/year

Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Advancing the Science of Blood Health
Publisher: ELSEVIER SCIENCE INCISSN: 1538-7933Frequency: 12 issues/year

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, published by Elsevier Science Inc, stands at the forefront of research in the fields of hematology and medicine, boasting an impressive ranking of #5 out of 137 in Scopus's Medicine - Hematology category, with a remarkable 96th percentile. As an essential resource for researchers, clinicians, and students, this journal, identifiable through its ISSN 1538-7933 and E-ISSN 1538-7836, encompasses pioneering studies and reviews that focus on the mechanisms of thrombosis and hemostasis, contributing significantly to advancements in patient care and therapeutic strategies. With an established presence from 2003 through 2024, it has consistently achieved a prestigious Q1 category ranking, reflecting its impactful contributions to the scientific community. Although it operates under a subscription-based model, the journal remains committed to disseminating significant findings that inform best practices in clinical settings and shape future research trajectories.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Elevating discourse in cardiovascular medicine.
Publisher: SPRINGERISSN: 0929-5305Frequency: 8 issues/year

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, published by Springer in the Netherlands, serves as a vital platform for research in the fields of Cardiology and Cardiovascular Medicine and Hematology. With an impressive impact factor, this journal ranks in the Q2 category for both fields according to the latest metrics, evidencing its significant influence and contribution to ongoing scholarly discourse. Spanning over three decades from 1994 to 2024, the journal provides an essential source for innovative studies, clinical practices, and comprehensive reviews related to thrombosis and thrombolysis. Researchers, clinicians, and students alike will find valuable insights and cutting-edge knowledge that address the complexities of blood coagulation and its implications in cardiovascular health. The journal is indexed in Scopus, with commendable rankings, further establishing its reputation in the academic community.

AMERICAN JOURNAL OF HEMATOLOGY

Empowering Discoveries in Blood Disorders
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

Hamostaseologie

Decoding Hemostasis: Your Source for Cutting-Edge Research and Reviews
Publisher: GEORG THIEME VERLAG KGISSN: 0720-9355Frequency: 4 issues/year

Hamostaseologie is a prominent academic journal dedicated to the field of hematology, published by GEORG THIEME VERLAG KG. With an ISSN of 0720-9355 and an E-ISSN of 2567-5761, this journal has been at the forefront of critical research and advancements since its inception in 1981, and it continues to maintain its relevance in the scientific community with a converged publication until 2024. Ranked in the Q3 quartile in Hematology for 2023, and positioned at #44 out of 137 in the Scopus Medicine Hematology category, it represents a substantial contribution to scholarly discourse. Researchers and professionals alike will find valuable insights within its pages, as it disseminates rigorous studies and reviews that address pertinent issues related to hemostasis and coagulation. While the journal does not currently offer Open Access, readers can access its valuable content through institutional subscriptions, making it an essential resource for students, clinicians, and researchers aiming to deepen their understanding of hematological science.

PLATELETS

Pioneering insights into the world of platelets.
Publisher: TAYLOR & FRANCIS INCISSN: 0953-7104Frequency: 8 issues/year

PLATELETS is a distinguished journal published by Taylor & Francis Inc that has been at the forefront of research in the fields of hematology and medicine since its inception in 1990. With an ISSN of 0953-7104 and an E-ISSN of 1369-1635, this journal boasts a solid reputation, as reflected by its Q2 ranking in both Hematology and Miscellaneous Medicine categories in 2023. PLATELETS serves as an essential platform for disseminating pioneering research, reviews, and case studies related to platelet biology, thrombosis, hemostasis, and their clinical implications. Although not an open-access publication, it is indexed in reputable databases, ensuring visibility and citation of quality contributions. Researchers, clinicians, and students alike will find valuable insights that may inform their work and enhance their understanding of the crucial role of platelets in health and disease. This journal's commitment to advancing knowledge and fostering innovation makes it a pivotal resource in the academic community.

THROMBOSIS RESEARCH

Elevating Hematology Through Rigorous Research
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0049-3848Frequency: 12 issues/year

THROMBOSIS RESEARCH is a leading peer-reviewed journal in the field of hematology, published by PERGAMON-ELSEVIER SCIENCE LTD. With an impressive impact factor and ranked within the top 10 of 137 in its category according to Scopus, this journal provides a critical platform for the dissemination of innovative research related to thrombosis and hemostasis. Established in 1972, THROMBOSIS RESEARCH has been at the forefront of scholarly communication, addressing key issues, findings, and advancements over more than five decades. Recognized for its high-quality content, the journal is categorized in the Q1 quartile for 2023, reflecting its influence and relevance within the scientific community. Researchers, medical professionals, and students engaged in the study of blood disorders will find valuable insights and the latest discoveries within its pages. Although currently not an open-access publication, THROMBOSIS RESEARCH remains accessible to a wide audience through institutional subscriptions, ensuring that vital research continues to inform and enhance clinical practices around the globe.

Journal of Hematology

Innovating Insights into Blood Disorders
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

THROMBOSIS AND HAEMOSTASIS

Exploring the Dynamics of Blood Clotting and Healing
Publisher: GEORG THIEME VERLAG KGISSN: 0340-6245Frequency: 12 issues/year

THROMBOSIS AND HAEMOSTASIS is a prestigious journal published by GEORG THIEME VERLAG KG, dedicated to advanced research in the field of hematology. With an esteemed Impact Factor and recognized as Q1 in its category for 2023, the journal is regarded for its pivotal role in disseminating significant findings that contribute to our understanding of thrombosis and hemostasis. Since its inception in 1976, this journal has continuously published cutting-edge studies and reviews, making it a vital resource for researchers, healthcare professionals, and students alike. The journal’s commitment to high-quality research is reflected in its impressive Scopus Ranking of #18 out of 137 in Medicine - Hematology, placing it in the 87th percentile among its peers. Although not currently open access, THROMBOSIS AND HAEMOSTASIS remains an authoritative source for exploring novel therapeutic strategies and the latest scientific advancements in the field. Based in Stuttgart, Germany, this journal serves as a critical platform for sharing knowledge and fostering collaboration within the global hematology community.